Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Rapport Therapeutics (RAPP) Return on Capital Employed (2024 - 2026)

Rapport Therapeutics (RAPP) has 3 years of Return on Capital Employed data on record, last reported at 25.09% in Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 603.0% to 25.09% in Q1 2026 year-over-year; TTM through Mar 2026 was 25.09%, a 603.0% increase, with the full-year FY2025 number at 31.7%, up 498.0% from a year prior.
  • Return on Capital Employed reached 25.09% in Q1 2026 per RAPP's latest filing, down from 24.78% in the prior quarter.
  • Over the last five years, Return on Capital Employed for RAPP hit a ceiling of 22.42% in Q3 2024 and a floor of 36.1% in Q2 2025.
  • A 3-year average of 27.68% and a median of 26.43% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: crashed -538bps in 2025, then skyrocketed 603bps in 2026.
  • Tracing RAPP's Return on Capital Employed over 3 years: stood at 26.43% in 2024, then increased by 6bps to 24.78% in 2025, then decreased by -1bps to 25.09% in 2026.
  • Business Quant data shows Return on Capital Employed for RAPP at 25.09% in Q1 2026, 24.78% in Q4 2025, and 27.8% in Q3 2025.